Skip to main content
. 2017 May 23;8(34):56714–56725. doi: 10.18632/oncotarget.18083

Figure 5. Kaplan-Meier estimates of PFS in 32 patients with metastatic sites of 3 or fewer.

Figure 5

The median PFS of patients treated with MWA plus EGFR-TKIs was 13.2 months (95%CI, 9.1-17.4 months), and those received EGFR-TKIs was 7.4 months (95%CI, 5.7-9.1 months).